Cory Baumann

Dr. Cory Baumann


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2020 in Experimental Physiology
Verified
Journal Article
Closed access
PDF file
ALAlexie A. Larson
Alexie A. Larson
CBCory Baumann
Cory Baumann
MKMichael Kyba
Michael Kyba
DLDawn A. Lowe
Dawn A. Lowe

11 August 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CBCory Baumann
Cory Baumann
HLHaiming M. Liu
Haiming M. Liu
LTLaDora V. Thompson
LaDora V. Thompson
It is well known that the ubiquitin-proteasome system is activated in response to skeletal muscle wasting and functions to degrade contractile proteins. The loss of these proteins inevitably reduces skeletal muscle size (i.e., quantity). However, it is currently unknown whether activation of this pathway also affects function by impairing the muscle’s intrinsic ability to produce force (i.e., quality). Therefore, the purpose of this study was twofold, (1) document how the ubiquitin-proteasome system responds to denervation and (2) identify the physiological consequences of these changes. To induce soleus muscle atrophy, C57BL6 mice underwent tibial nerve transection of the left hindlimb for 7 or 14 days (n = 6–8 per group). At these time points, content of several proteins within the ubiquitin-proteasome system were determined via Western blot, while ex vivo whole muscle contractility was specifically analyzed at day 14. Denervation temporarily increased several key proteins within the ubiquitin-proteasome system, including the E3 ligase MuRF1 and the proteasome subunits 19S, α7 and β5. These changes were accompanied by reductions in absolute peak force and power, which were offset when expressed relative to physiological cross-sectional area. Contrary to peak force, absolute and relative forces at submaximal stimulation frequencies were significantly greater following 14 days of denervation. Taken together, these data represent two keys findings. First, activation of the ubiquitin-proteasome system is associated with reductions in skeletal muscle quantity rather than quality. Second, shortly after denervation, it appears the muscle remodels to compensate for the loss of neural activity via changes in Ca2+ handling.

25 March 2016 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
CBCory Baumann
Cory Baumann
RRRussell George Rogers
Russell George Rogers
JOJeffrey Scott Otis
Jeffrey Scott Otis
CIChristopher Paul Ingalls
Christopher Paul Ingalls

2 August 2022 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Open access
SMSamantha E. Moser
Samantha E. Moser
ABAustin M. Brown
Austin M. Brown
BCBrian C. Clark
Brian C. Clark
WAW. David Arnold
W. David Arnold
CBCory Baumann
Cory Baumann
Background: Weakness is a common clinical symptom reported in individuals with chronic alcohol use disorder. However, it remains unclear whether low strength in these individuals is directly related to excessive ethanol intake, other deleterious factors (lifestyle, environment, genetics, etc.), or a combination of both. Therefore, we examined whether (and how) ethanol reduces the muscle’s force‐producing capacity using a controlled in vivo preclinical mouse model of excessive ethanol intake.Methods: To establish whether chronic ethanol consumption causes weakness, C57BL/6 female mice consumed 20% ethanol for 40 weeks (following a 2‐week ethanol ramping period), and various measures of muscular force were quantified. Functional measures included all‐limb grip strength and in vivo contractility of the left ankle dorsiflexors and plantarflexors. Once confirmed that mice consuming ethanol were weaker than age‐matched controls, we sought to determine the potential neuromuscular mechanisms of muscle dysfunction by assessing neuromuscular excitation, muscle quantity, and muscle quality.Results: Mice consuming chronic ethanol were 13 to 16% weaker (p ≤ 0.016) than controls (i.e., mice consuming 100% water) with the negative impact of ethanol on voluntary grip strength (ƞ2 = 0.603) being slightly larger than that of electrically stimulated muscle contractility (ƞ2 = 0.482). Relative to controls, lean mass and muscle wet masses were 9 to 16% lower in ethanol‐consuming mice (p ≤ 0.048, ƞ2 ≥ 0.268). No significant changes were observed between groups for indices of neuromuscular excitation at the level of the motor unit, neuromuscular junction, or plasmalemma (p ≥ 0.259, ƞ2 ≤ 0.097), nor was muscle quality altered after 40 weeks of 20% ethanol consumption (p ≥ 0.695, ƞ2 ≤ 0.012).Conclusions: Together, these findings establish that chronic ethanol consumption in mice induces a substantial weakness in vivo that we interpret to be primarily due to muscle atrophy (i.e., reduced muscle quantity) and possibly, to a lesser degree, loss of central neural drive.

18 January 2023 in Journal of General Physiology
Verified
Journal Article
Open access
PDF file
KLKiriaev Leonit
Kiriaev Leonit
CBCory Baumann
Cory Baumann
ALAngus Lindsay
Angus Lindsay
The absence of dystrophin hypersensitizes skeletal muscle of lower and higher vertebrates to eccentric contraction (ECC)-induced strength loss. Loss of strength can be accompanied by transient and reversible alterations to sarcolemmal excitability and disruption, triad dysfunction, and aberrations in calcium kinetics and reactive oxygen species production. The degree of ECC-induced strength loss, however, appears dependent on several extrinsic and intrinsic factors such as vertebrate model, skeletal muscle preparation (in vivo, in situ, or ex vivo), skeletal muscle hierarchy (single fiber versus whole muscle and permeabilized versus intact), strength production, fiber branching, age, and genetic background, among others. Consistent findings across research groups show that dystrophin-deficient fast(er)-twitch muscle is hypersensitive to ECCs relative to wildtype muscle, but because preparations are highly variable and sensitivity to ECCs are used repeatedly to determine efficacy of many preclinical treatments, it is critical to evaluate the impact of skeletal muscle preparations on sensitivity to ECC-induced strength loss in dystrophin-deficient skeletal muscle. Here, we review and discuss variations in skeletal muscle preparations to evaluate the factors responsible for variations and discrepancies between research groups. We further highlight that dystrophin-deficiency, or loss of the dystrophin–glycoprotein complex in skeletal muscle, is not a prerequisite for accelerated strength loss-induced by ECCs.

20 April 2022 in Journal of Muscle Research and Cell Motility
Verified
Journal Article
Closed access
PDF file
CBCory Baumann
Cory Baumann
CIChristopher P. Ingalls
Christopher P. Ingalls
DLDawn A. Lowe
Dawn A. Lowe